Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Implications of m6A modification in autoimmune disorders

Cellular & Molecular Immunology volume 17, pages 550–551 (2020)Cite this article

Subjects

N6-Methyladenosine (m6A) is the most common and abundant modification of RNA molecules, including mRNAs, microRNAs (miRNAs), and long noncoding RNAs (lncRNAs).1 The m6A modification is catalyzed and dynamically regulated by recently discovered enzymes termed ‘writers” (methyltransferases including METTL3, METTL14, and WTAP), ‘erasers” (demethylases including FTO and ALKBH5) and ‘readers” (m6A-binding proteins including YTHDC1, YTHDC2, YTHDF1, YTHDF2, and YTHDF3). These modifications were recently shown to be involved in the regulation of different biological processes, including the inflammatory and antitumor immune responses, antiviral immunity and T-cell homeostasis.2 More recent studies have shown that aberrant m6A modifications are associated with various pathophysiologies, including autoimmune diseases.

Autoimmune diseases (ADs) stem from the loss of immune tolerance to self-antigens and the involvement of specific organs, like type I diabetes mellitus, or multiple organs, like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and primary Sjögren’s syndrome (pSS). ADs affect ~8% of individuals worldwide, making them a leading cause of morbidity and mortality, as observed by a steep rise in their annual incidence rate. Although the etiology of ADs is typically multifactorial, genetics and environmental factors play a critical role in the pathogenesis of ADs.3

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Vu, L. P., Cheng, Y. & Kharas, M. G. The biology of m6A RNA methylation in normal and malignant hematopoiesis. Cancer Disco. 9, 25–33 (2019).

    Article  CAS  Google Scholar 

  2. Zhang, C., Fu, J. & Zhou, Y. A review in research progress concerning m6A methylation and immunoregulation. Front. Immunol. 10, 922 (2019).

    Article  CAS  Google Scholar 

  3. Wang, X. et al. A DNA-methylated sight on autoimmune inflammation network across RA, pSS, and SLE. J. Immunol. Res. 2018, 4390789 (2018).

    PubMed  PubMed Central  Google Scholar 

  4. Tong, J. et al. m6A mRNA methylation sustains Treg suppressive functions. Cell Res. 28, 253–256 (2018).

    Article  Google Scholar 

  5. Wang, H. et al. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation. Nat. Commun. 10, 1898 (2019).

    Article  Google Scholar 

  6. Han, D. et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1in dendritic cells. Nature 566, 270–274 (2019).

    Article  CAS  Google Scholar 

  7. Zong, X. et al. Mettl3 deficiency sustains long-chain fatty acid absorption through suppressing Traf6-dependent inflammation response. J. Immunol. 202, 567–578 (2019).

    Article  CAS  Google Scholar 

  8. Zhang, Y. et al. RNA-binding protein YTHDF3 suppresses interferon-dependent antiviral responses by promoting FOXO3 translation. Proc. Natl. Acad. Sci. USA. 116, 976–981 (2019).

    Article  CAS  Google Scholar 

  9. Rubio, R. M., Depledge, D. P., Bianco, C., Thompson, L. & Mohr, I. RNA m6 A modification enzymes shape innate responses to DNA by regulating interferon β. Genes Dev. 32, 1472–1484 (2018).

    Article  CAS  Google Scholar 

  10. Chen, Y. G. et al. N6-methyladenosine modification controls circular RNA immunity. Mol. Cell S1097–2765, 30546–30555 (2019).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. BRULAC-DRC, Saveetha Dental College & Hospital, Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha University, Chennai, India

    Arumugam Paramasivam & Jayaseelan Vijayashree Priyadharsini

  2. Centre for Biotechnology, Anna University, Chennai, India

    Subramanian Raghunandhakumar

Authors
  1. Arumugam Paramasivam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jayaseelan Vijayashree Priyadharsini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Subramanian Raghunandhakumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arumugam Paramasivam.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paramasivam, A., Priyadharsini, J.V. & Raghunandhakumar, S. Implications of m6A modification in autoimmune disorders. Cell Mol Immunol 17, 550–551 (2020). https://doi.org/10.1038/s41423-019-0307-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41423-019-0307-0

This article is cited by

Search

Advanced search

Quick links